3o0u
From Proteopedia
(Difference between revisions)
(3 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
+ | |||
==Cathepsin K covalently bound to a cyano-pyrimidine inhibitor with improved selectivity over hERG== | ==Cathepsin K covalently bound to a cyano-pyrimidine inhibitor with improved selectivity over hERG== | ||
- | <StructureSection load='3o0u' size='340' side='right' caption='[[3o0u]], [[Resolution|resolution]] 1.80Å' scene=''> | + | <StructureSection load='3o0u' size='340' side='right'caption='[[3o0u]], [[Resolution|resolution]] 1.80Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[3o0u]] is a 1 chain structure with sequence from [ | + | <table><tr><td colspan='2'>[[3o0u]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3O0U OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3O0U FirstGlance]. <br> |
- | </td></tr><tr id=' | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.8Å</td></tr> |
- | <tr id=' | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=O47:3-{2-[(E)-IMINOMETHYL]-6-PROPYLPYRIMIDIN-4-YL}-N,N-DIMETHYL-5-(TRIFLUOROMETHYL)BENZAMIDE'>O47</scene></td></tr> |
- | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3o0u FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3o0u OCA], [https://pdbe.org/3o0u PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3o0u RCSB], [https://www.ebi.ac.uk/pdbsum/3o0u PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3o0u ProSAT]</span></td></tr> | |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | |
</table> | </table> | ||
== Disease == | == Disease == | ||
- | [ | + | [https://www.uniprot.org/uniprot/CATK_HUMAN CATK_HUMAN] Defects in CTSK are the cause of pycnodysostosis (PKND) [MIM:[https://omim.org/entry/265800 265800]. PKND is an autosomal recessive osteochondrodysplasia characterized by osteosclerosis and short stature.<ref>PMID:8703060</ref> <ref>PMID:9529353</ref> <ref>PMID:10491211</ref> <ref>PMID:10878663</ref> |
== Function == | == Function == | ||
- | [ | + | [https://www.uniprot.org/uniprot/CATK_HUMAN CATK_HUMAN] Closely involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation. |
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Line 20: | Line 20: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
+ | <div class="pdbe-citations 3o0u" style="background-color:#fffaf0;"></div> | ||
==See Also== | ==See Also== | ||
- | *[[Cathepsin|Cathepsin]] | + | *[[Cathepsin 3D structures|Cathepsin 3D structures]] |
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
- | [[Category: Cathepsin K]] | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
- | [[Category: | + | [[Category: Large Structures]] |
- | [[Category: | + | [[Category: Fradera X]] |
- | [[Category: | + | [[Category: Uitdehaag JCM]] |
- | [[Category: | + | [[Category: Van Zeeland M]] |
- | + | ||
- | + | ||
- | + | ||
- | + |
Current revision
Cathepsin K covalently bound to a cyano-pyrimidine inhibitor with improved selectivity over hERG
|